Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD
H. Magnussen, O. Holz, H. Watz, M. Sauer, I. Khanskaya, L. Gann, P. Stryszak, H. Staudinger, J. Sadeh (Germany; Kenilworth, United States Of America)
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Session: Novel anti-inflammatory agents for airway disease
Session type: Oral Presentation
Number: 373
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Magnussen, O. Holz, H. Watz, M. Sauer, I. Khanskaya, L. Gann, P. Stryszak, H. Staudinger, J. Sadeh (Germany; Kenilworth, United States Of America). Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD. Eur Respir J 2010; 36: Suppl. 54, 373
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Effects of CXCR2 antagonists on neutrophil chemotaxis from COPD patients Source: Annual Congress 2010 - Airway cells as targets for anti-inflammatory drugs Year: 2010
Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2 Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects Source: Eur Respir J 2010; 35: 564-570 Year: 2010
Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012